Douglas Williams, Ph.D., will leave Biogen at the end of July to become CEO of as-yet unnamed start-up biotechnology company. Williams will be the first member of a new organization with potential in cancer diagnostics and therapy.

Responsibility for Biogen R&D will be assumed by Alfred Sandrock, M.D., Ph.D., senior vice president and chief medical officer, and Spyros Artavanis-Tsakonas, Ph.D., senior vice president and chief scientific officer. Both Sandrock and Artavanis-Tsakonas currently serve on the executive management team.